Sangamo BioSciences | SGMO - Current Liabilities


Sangamo BioSciences reported $47.66M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Alaunos Therapeutics USD 864K 269K Jun/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Amgen USD 23.23B 2.27B Sep/2026
Bayer EUR 29.4B 2.87B Sep/2026
BioCryst Pharmaceuticals USD 195.83M 13.02M Sep/2026
Biogen USD 3.9B 18.7M Sep/2026
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Cipla INR 69.77B 366.6M Sep/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.63M 596K Jun/2026
CSL USD 4.61B 207M Dec/2025
Gilead Sciences USD 12B 982M Sep/2026
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Grifols EUR 2.37B 156.97M Dec/2025
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
J&J USD 55.46B 562M Sep/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Merck USD 28.8B 1.07B Sep/2026
Novartis USD 32.52B 777M Sep/2026
Omeros USD 85.5M 2.28M Jun/2025
Pfizer USD 31.73B 920M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 29.77B 2.16B Sep/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Tectonic Therapeutic USD 10.37M 2.59M Jun/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026